Stay updated on Nivolumab & Ipilimumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab & Ipilimumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab & Ipilimumab in Melanoma Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page now displays the study record for CheckMate 064, including study design, participant eligibility, treatment arms, and outcome measures, instead of a 403 error.
    Difference
    54%
    Check dated 2026-11-08T04:32:56.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0; the study record content remains inaccessible behind a 403 error.
    Difference
    0.2%
    Check dated 2026-11-01T01:27:46.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T01:32:00.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.1 to v3.7.2 on the error page.
    Difference
    0.2%
    Check dated 2026-10-18T01:12:28.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The footer revision number was updated from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T01:46:57.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with a minimal header, replacing the prior study details with an error notice.
    Difference
    18%
    Check dated 2026-09-20T00:37:22.000Z thumbnail image

Stay in the know with updates to Nivolumab & Ipilimumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab & Ipilimumab in Melanoma Clinical Trial page.